175 related articles for article (PubMed ID: 15897584)
1. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Schwartz GK; O'Reilly E; Ilson D; Saltz L; Sharma S; Tong W; Maslak P; Stoltz M; Eden L; Perkins P; Endres S; Barazzoul J; Spriggs D; Kelsen D
J Clin Oncol; 2002 Apr; 20(8):2157-70. PubMed ID: 11956278
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Fekrazad HM; Verschraegen CF; Royce M; Smith HO; Chyi Lee F; Rabinowitz I
Am J Clin Oncol; 2010 Aug; 33(4):393-7. PubMed ID: 19884803
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
Cancer Chemother Pharmacol; 2005 Jul; 56(1):75-82. PubMed ID: 15809878
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Rathkopf D; Dickson MA; Feldman DR; Carvajal RD; Shah MA; Wu N; Lefkowitz R; Gonen M; Cane LM; Dials HJ; Winkelmann JL; Bosl GJ; Schwartz GK
Clin Cancer Res; 2009 Dec; 15(23):7405-11. PubMed ID: 19934304
[TBL] [Abstract][Full Text] [Related]
15. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Fornier MN; Rathkopf D; Shah M; Patil S; O'Reilly E; Tse AN; Hudis C; Lefkowitz R; Kelsen DP; Schwartz GK
Clin Cancer Res; 2007 Oct; 13(19):5841-6. PubMed ID: 17908977
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
